Helsinn Birex Therapeutics Ltd. announces the launch of the new 5-HT3 Receptor Antagonist ALOXI(r) (Palonosetron hydrochloride) EU/1/04/306/001 in Ireland
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...